Acefylline

Summary

Acefylline (CHEMBL70246) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 238.2 Da · C9H10N4O4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL70246
Name	Acefylline
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	69550
Molecular formula	C9H10N4O4
Molecular weight	238.2
InChIKey	HCYFGRCYSCXKNQ-UHFFFAOYSA-N

SMILES: CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC(=O)O

IUPAC name: 2-(1,3-dimethyl-2,6-dioxopurin-7-yl)acetic acid

Also known as: Acephylline, Caffeine carboxylic acid, Doxophylline metabolite m2, NSC-52996, SID170466658, Acefylline, ACEFYLLINE, acefylline

Parent form; salt/anhydrous children: CHEMBL2106660

Patent coverage: 428 distinct patent families (1,359 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Adenosine receptor A2b.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).